Nationwide trends and regional variation in intravitreal injections and anti-VEGF agent use in Japan (FY2017–FY2022)

This figshare item provides the derived datasets and analysis tables used in our nationwide observational study of intravitreal injections in Japan using NDB Open Data (FY2017–FY2022). Files include: (1) annual national totals for procedure code G016 and agent-specific anti-VEGF counts (aflibercept, ranibizumab, brolucizumab, faricimab) with the non–anti-VEGF remainder; (2) prefecture-level crude utilization rates (per 100,000 population); (3) sensitivity analyses addressing population aging (≥75-year denominator rates and indirect age-standardization using two age groups: